Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Prostatic Neoplasms 8Neuroendocrine Tumors 5Gastro-enteropancreatic neuroendocrine tumor 2Urogenital Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Diseases 1Prostate Cancer Metastatic 1Pheochromocytoma 1Paraganglioma 1Oligometastatic Prostate Cancer (OMPC) 1Neoplasms by Histologic Type 1Neoplasms 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lymphatic Diseases 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immune System Diseases 1Digestive System Neoplasms 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1

Interventions

Lutetium-177 1Lutetium 1Ga(III)-DOTATOC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Gastroenteropancreatic Neuroendocrine Tumor × Lutetium-177 × Clear all
NCT05884255 2026-05-19

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
220 enrolled
EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡